7 results
Based on the positive effects of Celecoxib on ultrafiltration and peritoneal injury during PD in rats, we would like to propose a pilot study using Celecoxib in PD-patients. In this pilot study we will investigate whether the Cox2 inhibitor…
The present proposal seeks to compare the cardiovascular and gastrointestinal safety and effectiveness of a strategy of initial randomisation to treatment with the selective COX-2 inhibitor celecoxib or to *usual-care* with their current non-…
The purpose of this extension is to provide continued treatment and to assess the long term safety, efficacy and tolerability of oral AEB071 plus Certican® vs. Neoral® plus Certican® in de novo renal transplant recipients. The study is a…
In the Netherlands, approximately 500 patients with FAP have been recognized, who are at high risk for developing duodenal carcinoma. Better insights in the pathogenesis of duodenal cancer and development of chemoprevention strategies are of pivotal…
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
To measure in vivo effect on neuroinflammation of treatment with celecoxib, a selective COX-2 inhibitor, in PD using PK111-95 and PET.Celecoxib showed broad utility in animal models of neurodegeneration. Neurochemical effect of the treatment on…
The primary objective is to test whether thrombolysis with additional contrast-enhanced ultrasound is applicable in patients with peripheral arterial occlusions. The secondary objectives are to investigate the safety of microbubble and ultrasound…